Charles Hesswani1, Yasser A Noureldin2, Mohamed A Elkoushy3, Sero Andonian1. 1. Division of Urology, McGill University Health Centre, McGill University, Montreal, QC; 2. Division of Urology, McGill University Health Centre, McGill University, Montreal, QC;; Department of Urology, Benha University Hospital, Benha University, Benha, Egypt; 3. Division of Urology, McGill University Health Centre, McGill University, Montreal, QC;; Department of Urology, Suez Canal University, Ismailia, Egypt.
Abstract
INTRODUCTION: We examined the effect of combined vitamin D and calcium supplementation (VDCS) on urinary calcium excretion and de novo stone formation in vitamin D inadequate (VDI) urolithiasis patients. METHODS: We retrospectively reviewed the data of VDI patients (serum 25-hydroxyvitamin D <75 nmol/L) followed at a tertiary stone centre between September 2009 and December 2014. VDI patients with history of urolithiasis, who were placed on VDCS for abnormal bone mineral density or hyperoxaluria, were included. Hypercalciuric patients and patients on thiazide diuretics were excluded. Metabolic stone workup and two 24-hour urine collections were performed before and after VDCS. RESULTS: In total, we included 34 patients, with a mean age of 54.8 years and a mean body mass index of 25.7 kg/m(2). After VDCS, there was a significant increase in the mean serum 25-hydroxyvitamin D (52.0 vs. 66.4 nmol/L, p < 0.001) and the mean urinary calcium excretion (3.80 vs. 5.64 mmol/d, p < 0.001). Eight (23.5%) patients developed de novo hypercalciuria. After a median follow-up of 39 (range: 7-60) months, 50% of hypercalciuric patients developed stones compared with 11.5% of non-hypercalciuric patients (p = 0.038). CONCLUSION: This study showed a significant effect of combined VDCS on mean urinary calcium excretion, de novo hypercalciuria, and stone development in VDI patients with history of urolithiasis. Therefore, VDI urolithiasis patients receiving VDCS are advised to have monitoring with 24-hour urine collections and imaging studies. Although small, our sample size was good enough to validate the statistical outcomes. Prospective studies are needed to confirm these results.
INTRODUCTION: We examined the effect of combined vitamin D and calcium supplementation (VDCS) on urinary calcium excretion and de novo stone formation in vitamin D inadequate (VDI) urolithiasispatients. METHODS: We retrospectively reviewed the data of VDI patients (serum 25-hydroxyvitamin D <75 nmol/L) followed at a tertiary stone centre between September 2009 and December 2014. VDI patients with history of urolithiasis, who were placed on VDCS for abnormal bone mineral density or hyperoxaluria, were included. Hypercalciuricpatients and patients on thiazide diuretics were excluded. Metabolic stone workup and two 24-hour urine collections were performed before and after VDCS. RESULTS: In total, we included 34 patients, with a mean age of 54.8 years and a mean body mass index of 25.7 kg/m(2). After VDCS, there was a significant increase in the mean serum 25-hydroxyvitamin D (52.0 vs. 66.4 nmol/L, p < 0.001) and the mean urinary calcium excretion (3.80 vs. 5.64 mmol/d, p < 0.001). Eight (23.5%) patients developed de novo hypercalciuria. After a median follow-up of 39 (range: 7-60) months, 50% of hypercalciuricpatients developed stones compared with 11.5% of non-hypercalciuricpatients (p = 0.038). CONCLUSION: This study showed a significant effect of combined VDCS on mean urinary calcium excretion, de novo hypercalciuria, and stone development in VDI patients with history of urolithiasis. Therefore, VDI urolithiasispatients receiving VDCS are advised to have monitoring with 24-hour urine collections and imaging studies. Although small, our sample size was good enough to validate the statistical outcomes. Prospective studies are needed to confirm these results.
Authors: David E Leaf; Ruslan Korets; Eric N Taylor; Jie Tang; John R Asplin; David S Goldfarb; Mantu Gupta; Gary C Curhan Journal: Clin J Am Soc Nephrol Date: 2012-03-15 Impact factor: 8.237
Authors: Heike A Bischoff-Ferrari; Edward Giovannucci; Walter C Willett; Thomas Dietrich; Bess Dawson-Hughes Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: Robert B Wallace; Jean Wactawski-Wende; Mary Jo O'Sullivan; Joseph C Larson; Barbara Cochrane; Margery Gass; Kamal Masaki Journal: Am J Clin Nutr Date: 2011-04-27 Impact factor: 7.045
Authors: Natalia O Kuchuk; Natasja M van Schoor; Saskia M Pluijm; Arkadi Chines; Paul Lips Journal: J Bone Miner Res Date: 2009-04 Impact factor: 6.741
Authors: Simon Hsu; David K Prince; Kayleen Williams; Norrina B Allen; Gregory L Burke; Andrew N Hoofnagle; Xiaohui Li; Kiang J Liu; Robyn L McClelland; Erin D Michos; Bruce M Psaty; Steven J Shea; Kenneth M Rice; Jerome I Rotter; David Siscovick; Russell P Tracy; Karol E Watson; Bryan R Kestenbaum; Ian H de Boer Journal: Am J Clin Nutr Date: 2022-03-04 Impact factor: 7.045
Authors: Nikhil Johri; Philippe Jaeger; Pietro M Ferraro; Linda Shavit; Devaki Nair; William G Robertson; Giovanni Gambaro; Robert J Unwin Journal: Urolithiasis Date: 2016-12-16 Impact factor: 3.436